Recognizing neuromyelitis optica spectrum disorder (NMOSD) and differentiating NMOSD from multiple sclerosis (MS) and other disorders can be challenging yet it is extremely important to prevent misdiagnosis, defined in this review as the incorrect diagnosis of patients who truly have NMOSD, particularly in aquaporin-4-IgG (AQP4-IgG)-seronegative cases. The heterogeneity of clinical presentations and wide range of differential diagnoses often lead to missed diagnoses of NMOSD. Misapplication of the 2015 NMOSD criteria and misinterpretation of clinical and neuroradiological findings are relevant factors associated with misdiagnosis in clinical practice. Despite the presence of a specific biomarker for NMOSD (AQP4-IgG), misdiagnosis rates have been reported as high as 35%. Studies indicate that misdiagnosed patients often undergo unnecessary prolonged immunotherapy, leading to health risks and increased morbidity. Accurate definitive diagnosis is crucial as long-term outcomes and treatment approaches differ based on the correct diagnosis, and inappropriate immunotherapy can lead to disability in NMOSD patients. This review outlines factors linked to NMOSD misdiagnosis and briefly discusses strategies to reduce misdiagnosis.
WingerchukDMBanwellBBennettJL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology2015; 85(2): 177–189.
2.
BanwellBBennettJLMarignierR, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol2023; 22(3): 268–282.
3.
Carnero ContenttiELópezPACrinitiJ, et al. Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors. Mult Scler2023; 29(2): 277–286.
4.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
5.
KimSMKimSJLeeHJ, et al. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord2017; 10(7): 265–289.
6.
PalaceJLinDYZengD, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain2019; 142(5): 1310–1323.
7.
BeekmanJKeislerAPedrazaO, et al. Neuromyelitis optica spectrum disorder: Patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm2019; 6(4): e580.
8.
SmithADMoogTMBurgessKW, et al. Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder. Mult Scler Relat Disord2023; 70: 104498.
9.
JariusSRuprechtKWildemannB, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation2012; 9: 14.
10.
ZaraPDinotoACartaS, et al. Non-demyelinating disorders mimicking and misdiagnosed as NMOSD: A literature review. Eur J Neurol2023; 30(10): 3367–3376.
11.
Carnero ContenttiERojasJICristianoE, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord2020; 45: 102428. Erratum in: Mult Scler Relat Disord 2021; 52: 103026.
12.
MinJHCapobiancoMWelshC, et al. Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews. Neurol Ther2023; 12(2): 619–633.
13.
Carnero ContenttiEOkudaDTRojasJI, et al. MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. J Neuroimaging2023; 33(5): 688–702.
14.
SzewczykAKPapućEMitosek-SzewczykK, et al. NMOSD-Diagnostic Dilemmas Leading towards Final Diagnosis. Brain Sci2022; 12(7): 885.
15.
AvasaralaJPettigrewCSuttonP, et al. Can a diagnosis of multiple sclerosis be made without ruling out neuromyelitis optica spectrum disorder?Mult Scler Relat Disord2020; 40: 101949.
16.
SolomonAJArrambideGBrownleeWJ, et al. Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. Lancet Neurol2023; 22(8): 750–768.
17.
FlanaganEPKaufmannTJKreckeKN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol2016; 79(3): 437–447.
18.
AkaishiTTakahashiTMisuT, et al. Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Sci Rep2020; 10(1): 13890.
19.
RotsteinDLFreedmanMSLeeL, et al. Predicting time to serologic diagnosis of AQP4+ NMOSD based on clinical factors and social determinants of health. Mult Scler Relat Disord2024; 83: 105434.
20.
SchmetzerOLakinERoedigerB, et al. Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder. Front Neurol2021; 12: 635419.
21.
JuryńczykMWeinshenkerBAkman-DemirG, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol2016; 263(1): 140–149.
22.
WangXShiZZhaoZ, et al. The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases. Front Immunol2022; 13: 959469.
23.
LinLHangHZhangJ, et al. Clinical significance of anti-SSA/Ro antibody in Neuromyelitis optica spectrum disorders. Mult Scler Relat Disord2022; 58: 103494.
24.
WangRSunDRDuQ, et al. Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder. J Neuroimmunol2023; 382: 578151.
25.
ZandonáMEKimSHHyunJW, et al. The onset location of neuromyelitis optica spectrum disorder predicts the location of subsequent relapses. Mult Scler2014; 20(14): 1908–1911.
26.
Carnero ContenttiEDaccach MarquesVSoto de CastilloI, et al. Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients. Mult Scler Relat Disord2018; 19: 73–78.
27.
CacciaguerraLMeaniAMesarosS, et al. Brain and cord imaging features in neuromyelitis optica spectrum disorders. Ann Neurol2019; 85(3): 371–384.
28.
KimHJPaulFLana-PeixotoMA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology2015; 84(11): 1165–1173.
29.
D’SouzaMPapadopoulouALevyM, et al. Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. Mult Scler Relat Disord2020; 41: 102027.
30.
ClarkeLArnettSBukhariW, et al. MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Front Neurol2021; 12: 722237.
31.
SinneckerTClarkeMAMeierD, et al. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurol2019; 76(12): 1446–1456. Erratum in: JAMA Neurol 2020; 77(8): 1040.
32.
La RosaFWynenMAl-LouziO, et al. Cortical lesions, central vein sign, and paramagnetic rim lesions in multiple sclerosis: Emerging machine learning techniques and future avenues. Neuroimage Clin2022; 36: 103205.
33.
YonezuTItoSMoriM, et al. “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler2014; 20(3): 331–337.
34.
WeinshenkerBGWingerchukDMGreenAJ, et al. Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum. Mult Scler2023; 29(8): 945–955.
35.
JurynczykMGeraldesRProbertF, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain2017; 140(3): 617–627.
36.
Carnero ContenttiERojasJICrinitiJ, et al. Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: Large multi-ethnic population and different clinical scenarios. Mult Scler Relat Disord2022; 61: 103778.
37.
CaiMTZhengYShenCH, et al. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder. Mult Scler2021; 27(6): 871–882.
38.
CorteseRPrados CarrascoFTurC, et al. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging. Neurology2023; 100(3): e308–e323.
39.
WatersPReindlMSaizA, et al. Multicentre comparison of a diagnostic assay: Aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry2016; 87(9): 1005–1015.
40.
KunchokAChenJJMcKeonA, et al. Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients. JAMA Neurol2020; 77(2): 257–259.
41.
HolroydKVogelALynchK, et al. Neuromyelitis optica testing and treatment: Availability and affordability in 60 countries. Mult Scler Relat Disord2019; 33: 44–50.
42.
MajedMValencia SanchezCBennettJL, et al. Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis. Ann Neurol2023; 94(4): 727–735.
43.
KimSLeeJJParkJS, et al. Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: A comprehensive review and integrated analysis with glial fibrillary acidic protein. Neurol Sci2024; 45(3): 1255–1261.
